France to Ban HHC Synthetic Cannabis in Weeks

May.16.2023
France to Ban HHC Synthetic Cannabis in Weeks
France's Health Minister plans to ban HHC products, created from synthetic cannabis extract, within weeks due to regulatory loopholes.

Statement:


This article is solely focused on conducting research on related industries and foreign markets. It does not make recommendations on any products, nor does it provide commentary on any domestic policies pertaining to the industry.


The legality of the product mentioned in the article is limited to overseas only. Domestic readers are reminded to strictly abide by relevant laws and regulations in China.


This article does not provide any investment or consumption advice.


This article is not suitable for minors.


On May 15th, François Braun, the French Minister of Health, announced that products containing HHC (hexahydrocannabinol) may be banned in a few weeks.


When asked about issues related to hexahydrocannabinol (HHC) by the media, Braun told French radio station, "...


I believe that this (ban) will only be in effect for a few weeks.


According to reports, HHC is a molecule artificially synthesized from natural cannabis extract, and products based on HHC are currently not subject to sales or consumption restrictions in France.


In the past few months, health authorities in various countries, both in Europe and the United States, have noticed an increase in the sale of a certain substance through online or physical stores. Currently, not much is known about its effects, but addiction experts believe it has similar effects to tetrahydrocannabinol (THC), which is the primary psychoactive ingredient in cannabis.


Braun explained, "Currently, they are not classified as drugs. But I believe they will soon be.


Braun likened HHC to a regulatory loophole.


There is a loophole that needs to be quickly filled so that we no longer have such completely abnormal sales.


Reference:


The Health Minister announces that synthetic cannabis, HHC, will be banned within a few weeks.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Product | Philip Morris Launches TEREA Bold Red and Bold Black in Germany With Level-10 Tobacco Intensity at €8 per Pack
Product | Philip Morris Launches TEREA Bold Red and Bold Black in Germany With Level-10 Tobacco Intensity at €8 per Pack
Philip Morris International (PMI) introduced TEREA Bold Red and Bold Black heated tobacco sticks in Germany in October 2026, both carrying a brand-rated tobacco-flavor intensity of 10, the highest level in the country's TEREA portfolio. Bold Red features leather and warm woody notes, while Bold Black combines woody and subtle floral notes. Both are sold in 20-stick packs at €8, approximately 2.6% above standard TEREA products. Germany's TEREA range now includes 11 flavor variants, alongside a separate 26-stick XL format priced at €10. IQOS Germany announced the new products on October 12, followed by a phased retail rollout from late October and an IQOS Club campaign running through December.
product
Nov.02
Imperial Brands Plans to Cut Nearly 18% of Workforce as German Plant Closure and Polish Outsourcing Drive Restructuring
Imperial Brands Plans to Cut Nearly 18% of Workforce as German Plant Closure and Polish Outsourcing Drive Restructuring
Imperial Brands disclosed on November 17, 2026, that its global manufacturing and organisational restructuring is expected to reduce between 4,200 and 4,600 roles by the end of 2030, equivalent to approximately 16%–18% of its workforce at the end of 2025. The first phase covers 2,100 roles with departures confirmed or subject to consultation, while a further 2,100–2,500 positions are expected to be eliminated by 2030. The company is proceeding with the closure of its Langenhagen factory in Germany, has sold its manufacturing facility in Taiwan, and has transferred selected finance, procurement and supply-chain operations in Poland to Capgemini. The restructuring programme is expected to cost approximately £740 million, with Imperial targeting at least £320 million in annual cost savings by 2030.
company
Nov.18
On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
FDA’s Center for Tobacco Products detailed new PMTA review data and process changes at the 2026 FDLI conference. Pending PMTAs fell from about 450,000 at the start of 2025 to 135,000 by September 2026. CTP also discussed its 180-day review goal, current sPMTA pilot, alternate-supplier planning, more than 50,300 pending SE reports, and lessons from the nicotine pouch pilot already being applied to ENDS review.
Regulations
Oct.07
Special Report | From Oversupply to Supply Gaps: Global Tobacco Leaf Markets Diverge Ahead of 2027
Special Report | From Oversupply to Supply Gaps: Global Tobacco Leaf Markets Diverge Ahead of 2027
Global tobacco leaf markets diverged sharply in 2026, with India cutting authorised FCV production amid oversupply while Malawi faced a supply shortfall. U.S. demand improved in some leaf categories, but growers in Brazil, Colombia, Tanzania and Zimbabwe faced pressure from prices, buyer access, costs and weather. With nicotine consumption patterns also shifting, 2027 will test whether supply, demand and grower profitability can move back toward balance.
Oct.26
Altria Showcases Ploom, Marlboro Heated Tobacco Sticks and Non-Nicotine Energy Products at NACS Show 2026
Altria Showcases Ploom, Marlboro Heated Tobacco Sticks and Non-Nicotine Energy Products at NACS Show 2026
At the 2026 NACS Show, Altria displayed Ploom devices alongside imagery of Marlboro-branded heated tobacco sticks, while also featuring RIOT Energy and Proper Wild non-nicotine products. The booth showcased on! PLUS nicotine pouches, including 12 mg variants not listed among FDA-authorized products as of October 9, and NJOY e-cigarettes. Altria also presented convenience-store traffic figures highlighting its retail presence. 2Firsts examines the company's expanded product portfolio, non-nicotine business activities and the regulatory status of products displayed at the show.
EXPO
Oct.10
China’s Vape-Related Exports Rose 4.5% in Q3 2026 as 21.6% Growth in Shipments to the UK Offset a Decline in Shipments to the US
China’s Vape-Related Exports Rose 4.5% in Q3 2026 as 21.6% Growth in Shipments to the UK Offset a Decline in Shipments to the US
China's vape-related exports rose 4.5% year over year to $2.86 billion in the third quarter of 2026, led by stronger shipments to the United Kingdom as exports to the United States declined. UK-bound shipments increased 21.6%, adding $81.9 million, while US exports fell 5.2%, or $53.6 million. Growth weakened through the quarter, with September exports down 6.3% globally and 37.8% to the US. Nicotine-containing vape products accounted for more than 82% of the quarterly net increase, while device exports were nearly flat. Nine-month exports totaled $7.82 billion, up 4.0%.
DATA
Oct.26